Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EMERGING TREATMENTS FOR HUNTER SYNDROME
5.1 TREATMENT: DNL310
5.2 TREATMENT: JR141
5.3 TREATMENT: TAK-609/SHP609/HGT-2310
5.4 TREATMENT: RGX-121
5.5 TREATMENT: SB-913
5.6 TREATMENT: AVR-RD-05
5.7 TREATMENT: ODIPARCIL
5.8 TREATMENT: AGT-181
5.9 TREATMENT: EGT-301
6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II)
6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME
6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME
6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME
8.1.2 RISING ADOPTION OF GENE THERAPY
8.1.3 INCREASING GOVERNMENT INITIATIVES
8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS
8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT
8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME
8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II
8.3 OPPORTUNITIES
8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT
8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS
8.4 CHALLENGES
8.4.1 LIMITATIONS OF CURRENT TREATMENT
8.5 IMPROPER REIMBURSEMENT POLICIES
9 IMPACT OF COVID-19 ON THE NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MODERATE TO SEVERE
10.3 MILD TO MODERATE
11 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 ENZYME REPLACEMENT THERAPY
11.2.1 ELAPRASE + TAK-609
11.2.2 HUNTERASE
11.2.3 IZCARGO
11.3 STEM CELL TRANSPLANT
11.3.1 UMBILICAL CORD TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
11.4 SURGICAL TREATMENT
11.4.1 CARDIAC VALVE REPLACEMENT SURGERY
11.4.2 TRACHEOSTOMY
11.4.3 POSITIVE AIRWAY PRESSURE DEVICES
11.4.4 JOINT CONTRACTURES
11.4.5 ABDOMINAL HERNIA SURGERY
11.4.6 OTHERS
11.5 OTHERS
12 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS
12.1 OVERVIEW
12.2 RESPIRATORY DISORDERS
12.3 NEUROLOGICAL DISORDERS
12.4 CARDIOVASCULAR
12.5 MUSCULOSKELETAL
12.6 GASTROINTESTINAL DISORDERS
12.7 OPHTHALMIC
12.8 AUDIOLOGIC
12.9 DENTAL
12.1 OTHERS
13 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 GREEN CROSS CORP.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 ABBOTT
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENTS
18.4 AVROBIO, INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 PRODUCT PORTFOLIO
18.4.3 RECENT DEVELOPMENTS
18.5 BD
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 CANBRIDGE LIFE SCIENCES LTD.
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 DENALI THERAPEUTICS
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 HOMOLOGY MEDICINES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 TECHNOLOGY PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 INVENTIVA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 JASPER THERAPEUTICS, INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 JCR PHARMACEUTICALS CO., LTD.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 JOHNSON & JOHNSONS SERVICES, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 MEDTRONIC
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 PFIZER INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 REGENXBIO INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 SANGAMO THERAPEUTICS
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 STRYKER
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.2 UCB S.A.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA MILD TO MODERATE IN NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
TABLE 23 NORTH AMERICA HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
TABLE 28 NORTH AMERICA HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 U.S. HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 42 U.S. HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 43 U.S. ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 U.S. STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 U.S. SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 U.S. HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 47 U.S. HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 48 U.S. HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 CANADA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 50 CANADA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 CANADA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 CANADA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 CANADA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 CANADA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 55 CANADA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 CANADA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 MEXICO HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 MEXICO HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 MEXICO ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 MEXICO STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 MEXICO SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 MEXICO HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 63 MEXICO HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 MEXICO HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
FIGURE 2 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET
FIGURE 14 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 17 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
FIGURE 18 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 19 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 20 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 21 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 22 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 23 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028)
FIGURE 24 NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%)
